Neurology & Brain Disorders Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease

This Phase 3 trial led by Samsung Pharmaceutical is testing a new medicine called GV1001 for people with moderate to severe Alzheimer's disease. The treatment is given as a subcutaneous injection, which means it is injected just under the skin. If the study shows positive results after 24 weeks, GV1001 could become a new option to help improve thinking abilities and quality of life for many patients facing this challenging stage of Alzheimer’s.

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Takeda’s Phase 3 trial evaluated soticlestat as an additional treatment for people with two rare and severe forms of epilepsy called Dravet Syndrome and Lennox-Gastaut Syndrome. The study included 352 participants from multiple locations worldwide. The results, now available, may provide hope for reducing seizures and improving daily life for children and adults living with these difficult-to-treat conditions.

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

This Phase 2 study conducted at St. Joseph's Hospital and Medical Center in Phoenix is testing lenalidomide, a medicine that affects the immune system, in people with mild cognitive impairment linked to Alzheimer’s disease. By targeting inflammation in the brain, this approach aims to slow down memory loss and brain changes. Although only 15 participants were enrolled, the results could lead to new ways to protect brain function early in the disease process.

German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation

Heinrich-Heine University in Duesseldorf is running a study in Germany to evaluate transcranial pulse wave stimulation, a non-drug therapy for Alzheimer’s disease. This treatment uses sound waves to stimulate the brain and may help improve symptoms or slow disease progression. With plans to enroll 100 patients, this research could offer a new option for those seeking alternatives to medications.

Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease

This trial in France is testing a new memory training technique that uses physical movement to help people with early-stage Alzheimer’s remember information better. By engaging parts of the brain linked to movement, the method may improve memory recall and daily functioning without using drugs. Recruiting 80 participants, this study offers a promising approach to support brain health through simple exercises.

This week’s research brings encouraging developments across drug and non-drug treatments for Alzheimer’s and rare epilepsy syndromes. New therapies aim to improve symptoms, slow progression, and enhance quality of life. TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.